Table 1.

Proportional hazard calculations for each of the three MMR genes with significant effect on clinical outcome measured by overall survival: MLH1, PMS1, and PMS2

FactorHRConfidence intervalP value
MLH1hi
MLH1lo1.611.07–2.430.02a
PR
PR+0.780.54–1.130.19
ERBB2
ERBB2+1.310.87–1.990.19
Stage 0
Stage I0.470.26–0.850.01a
Stage II0.870.59–1.280.48
Stage III1.460.68–3.130.33
Stage IV2.240.31–16.480.43
TP53WT
TP53mut1.971.01–3.850.04a
PMS1hi
PMS1lo1.371.01–1.860.04a
PR
PR+0.740.54–1.020.07b
ERBB2
ERBB2+1.460.2–10.690.71
Stage 0
Stage I0.520.33–0.830.005a
Stage II0.90.63–1.290.58
Stage III1.80.89–3.640.1b
Stage IV2.030.28–14.760.48
TP53WT
TP53mut1.961.07–3.570.03a
PMS2hi
PMS2lo1.861.201–2.6990.004a
PR
PR+0.790.55–1.150.23
ERBB2
ERBB2+1.370.91–2.090.13
Stage 0
Stage I0.50.28–0.920.03a
Stage II0.940.63–1.390.76
Stage III1.790.82–3.910.14
Stage IV2.370.32–17.430.4
TP53WT
TP53mut2.111.07–4.140.03a
  • NOTE: Cox regression was used to calculate P values.

  • aP < 0.05.

  • bP ≤ 0.1.